IBX Share Price Performance
AU$0.016
-0.02 (-57.89%)
Price AU$0.016
Share PriceAU$0.016
IBX Community Narratives
There are no narratives available yet.
Recent IBX News & Updates
No updates
Imagion Biosystems Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.01
- Gross Margin
- 84.95%
- Net Profit Margin
- -77.56%
- Debt/Equity Ratio
- -122.4%
Imagion Biosystems Limited Competitors
About IBX
- Founded
- 2016
- Employees
- n/a
- CEO
- WebsiteView website
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Australian Market Performance
- 7 Days: -0.4%
- 3 Months: 6.8%
- 1 Year: 13.2%
- Year to Date: 5.2%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 13% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading